What one share of Caris Life Sciences holds
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.50 |
|---|---|
| Profit | $0.37 |
| Debt | $1.39 |
| Book value | $2.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $8.76 | −$13.24 | $0.64 | −$8.54 | — | −$61.38 |
| 2024 | $11.61 | −$10.66 | $0.24 | −$7.15 | — | −$68.45 |
| 2025 | $4.86 | −$3.22 | $0.10 | $0.40 | — | $2.04 |
Common questions about Caris Life Sciences
How much does one share of Caris Life Sciences earn?
Over the last 12 months, each share of Caris Life Sciences earned $0.37 of profit on $3.50 of sales, keeping about 11¢ of every $1 (profit margin).
Does Caris Life Sciences pay a dividend?
Caris Life Sciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Caris Life Sciences’s book value per share?
Caris Life Sciences’s book value is $2.09 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Caris Life Sciences have?
Each share of Caris Life Sciences has $1.39 of debt, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.